12.5.2.30 DHS rekommandationer for KMT 2011.pdf - e-Dok

Lenz G, Dreyling M, Schiegnitz E, et al. Myeloablative radiochemotherapy followed by autologous
stem cell transplantation in first remission prolongs progression-free survival in follicular
lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study
Group. Blood 2004; 104: 2667-74.
Gyan E, Foussard C, Bertrand P et al. High dose therapy followed by autologous purged stem cell
transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: A
randomized multicenter study by the GOELAMS. Final results with a median follow-up of nine years.
Blood. 2009; 113: 995-1001.
Schouten HC, Qian W, Kvaloy S, et al. High-dose therapy improves progression-free survival and
survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP
trial. J Clin Oncol 2003; 21:3918-27.
Sebban C, Brice P, Delarue R et al. Impact of rituximab and/or high-dose therapy with autotransplant at time of
relapse in patients with follicular lymphoma: a GELA study.
J Clin Oncol. 2008; 26: 3614-20.
Tarella C, Zanni M, Magni M et al. Rituximab improves the efficacy of high-dose chemotherapy with autograft for
high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innnovative nei
Linfomi survey. J Clin Oncol. 2008; 26: 3166-75.
van Besien K. Autologous and allogeneic stem cell transplantation in follicular lymphoma.
Transfus Apher Sci 2005; 32:45-53 (Review).
van Besien K, Loberiza FR, Bajorunaite R, et al. Comparison of autologous and allogeneic
hematopoietic stem cell transplantation for follicular lymphoma. Blood 2003; 102:3521-9.
Allogen transplantation
Avivi I, Montoto S, Canals C et al. Matched unrelated donor stem cell transplant in 131 patients with follicular
lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow
Transplantation. British Journal of Haematology 2009; 147: 719-28.
Bethge WA, Lange T, Meisner C et al. Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan as part of a
reduced-intensity conditioning regimen for allogeneic hematopoietic cell transplantation in patients with
advanced non-Hodgkin lymphoma. Results of a phase 2 study. Blood 2010, 116: 1795-802.
Bloor AJC, Thomson K, Chowdbry N et al. High response rate to donor lymphocyte infusion after allogeneic
stem cell transplantation for indolent non-hodgkin lymphoma. Biology of Blood and Marrow Transplantation
2008; 14: 50-58.
De Lavallade H, Mohty M, El-Cheikl J et al. Reduced-intensity conditioning allogeneic stem cell transplantation
for patients with chemoresistant or relapsed follicular lymphoma. British Journal of Haematology 2006; 135: 408-
410.
Faulkner RD, Craddock C, Byrne JL, et al. BEAM-alemtuzumab reduced-intensity allogeneic stem cell
82